HRP20180523T1 - Antagonisti receptora 5-ht3 - Google Patents

Antagonisti receptora 5-ht3

Info

Publication number
HRP20180523T1
HRP20180523T1 HRP20180523TT HRP20180523T HRP20180523T1 HR P20180523 T1 HRP20180523 T1 HR P20180523T1 HR P20180523T T HRP20180523T T HR P20180523TT HR P20180523 T HRP20180523 T HR P20180523T HR P20180523 T1 HRP20180523 T1 HR P20180523T1
Authority
HR
Croatia
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
HRP20180523TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephen Hitchcock
Holger Monenschein
Holly REICHARD
Huikai SUN
Shota Kikuchi
Todd MACKLIN
Maria HOPKINS
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48877569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20180523T1 publication Critical patent/HRP20180523T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/38—Acyl halides
    • C07C53/40—Acetyl halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20180523TT 2012-07-17 2013-07-16 Antagonisti receptora 5-ht3 HRP20180523T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672709P 2012-07-17 2012-07-17
US201261708521P 2012-10-01 2012-10-01
EP13742355.4A EP2875011B1 (en) 2012-07-17 2013-07-16 5-ht3 receptor antagonists
PCT/US2013/050746 WO2014014951A1 (en) 2012-07-17 2013-07-16 5-ht3 receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20180523T1 true HRP20180523T1 (hr) 2018-06-01

Family

ID=48877569

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180523TT HRP20180523T1 (hr) 2012-07-17 2013-07-16 Antagonisti receptora 5-ht3

Country Status (43)

Country Link
US (8) US9012447B2 (en:Method)
EP (3) EP3312169B1 (en:Method)
JP (5) JP5816400B2 (en:Method)
KR (1) KR102148969B1 (en:Method)
CN (2) CN106478662B (en:Method)
AP (1) AP2015008240A0 (en:Method)
AR (1) AR091781A1 (en:Method)
AU (1) AU2013290375B2 (en:Method)
BR (1) BR112015001028B1 (en:Method)
CA (1) CA2879115C (en:Method)
CL (1) CL2015000121A1 (en:Method)
CO (1) CO7280468A2 (en:Method)
CR (1) CR20150057A (en:Method)
CY (1) CY1120881T1 (en:Method)
DK (2) DK2875011T3 (en:Method)
DO (1) DOP2015000009A (en:Method)
EA (1) EA025986B1 (en:Method)
EC (1) ECSP15004780A (en:Method)
ES (2) ES2659758T3 (en:Method)
GE (1) GEP201606526B (en:Method)
HR (1) HRP20180523T1 (en:Method)
HU (2) HUE056710T2 (en:Method)
IL (1) IL236702B (en:Method)
IN (1) IN2015DN00957A (en:Method)
JO (1) JOP20130213B1 (en:Method)
LT (1) LT2875011T (en:Method)
ME (1) ME03005B (en:Method)
MX (1) MX359733B (en:Method)
MY (1) MY182432A (en:Method)
NZ (1) NZ704814A (en:Method)
PE (1) PE20150671A1 (en:Method)
PH (1) PH12015500085A1 (en:Method)
PL (2) PL3312169T3 (en:Method)
PT (2) PT2875011T (en:Method)
RS (1) RS57096B1 (en:Method)
SG (1) SG11201500302UA (en:Method)
SI (1) SI2875011T1 (en:Method)
SM (1) SMT201800177T1 (en:Method)
TN (1) TN2015000018A1 (en:Method)
TW (1) TWI602821B (en:Method)
UY (1) UY34912A (en:Method)
WO (2) WO2014014962A1 (en:Method)
ZA (1) ZA201500781B (en:Method)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
KR101920472B1 (ko) * 2014-03-06 2019-02-08 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 오렉신 수용체 길항제로서의 피페리딘 유도체
DK3201203T3 (da) * 2014-09-29 2021-08-23 Takeda Pharmaceuticals Co Krystallinsk form af 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indol-3-carboxamid
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
BR112019020100A2 (pt) * 2017-03-27 2020-05-05 Chase Therapeutics Corp composições e métodos para tratar sinucleinopatias
IL270104B (en) 2017-04-24 2022-07-01 Chase Therapeutics Corp Combination of pramipexole and a 5ht3 antagonist for use in treating depression
CA3104811C (en) 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
WO2019180176A1 (en) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition for the treatment of schizophrenia and/or psychosis
WO2020068913A1 (en) * 2018-09-25 2020-04-02 Chase Therapeutics Corporation Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
WO2021026380A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Phenyltriazole compounds for the treatment of pain
CN119156388A (zh) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
WO2025077825A1 (en) * 2023-10-13 2025-04-17 Fauna Bio Incorporated Methods and compositions for treating cardio-pulmonary disorders

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4273963A (en) 1979-05-25 1981-06-16 Bell Telephone Laboratories, Incorporated Automatic equalization for digital transmission systems
DE3033568A1 (de) 1980-09-05 1982-05-06 Marker, Hannes, 8100 Garmisch-Partenkirchen Fersenhalter einer sicherheits-skibindung
JPS5816400A (ja) 1981-07-21 1983-01-31 松下電器産業株式会社 交通信号制御機
FR2531083B1 (fr) 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
GB8525913D0 (en) 1985-10-21 1985-11-27 Beecham Group Plc Compounds
EP0200444B1 (en) 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8510752D0 (en) * 1985-04-27 1985-06-05 Beecham Group Plc Compounds
JPS6275675A (ja) 1985-09-30 1987-04-07 Toshiba Corp 画像形成装置
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3722069A1 (de) 1986-08-21 1988-02-25 Toyoda Gosei Kk Signalhornschaltvorrichtung fuer ein steuerrad
WO1988003801A1 (en) 1986-11-21 1988-06-02 Glaxo Group Limited Medicaments for treatment or prevention of withdrawal syndrome
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
NZ230068A (en) 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
JPH0421681A (ja) * 1990-05-14 1992-01-24 Fujisawa Pharmaceut Co Ltd ピロロピリジン誘導体
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
JP3251954B2 (ja) * 1990-07-31 2002-01-28 日清ファルマ株式会社 アザビシクロ誘導体
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5149962A (en) 1991-06-03 1992-09-22 Simmonds Precision Products, Inc. Proximity detector using faraday effect and bidirectional transmission
JP3407916B2 (ja) * 1992-01-31 2003-05-19 日清ファルマ株式会社 ジアザビシクロ誘導体
US5344831A (en) 1992-01-31 1994-09-06 Nisshin Flour Milling Co., Ltd. Diazabicyclo derivatives
GB9216154D0 (en) 1992-07-30 1992-09-09 Glaxo Group Ltd Chemical compounds
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
WO1996012722A1 (en) * 1994-10-20 1996-05-02 Nisshin Flour Milling Co., Ltd. 5-ht4 receptor agonist
JP3904254B2 (ja) * 1994-10-20 2007-04-11 株式会社日清製粉グループ本社 ５−ｈｔ４受容体作動薬
CA2160420A1 (en) 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
AU2319100A (en) * 1999-01-28 2000-08-18 Nippon Shinyaku Co. Ltd. Amide derivatives and drug compositions
WO2001043746A1 (en) * 1999-12-14 2001-06-21 Nippon Shinyaku Co., Ltd. Medicinal composition
BR0212613A (pt) 2001-09-19 2004-08-31 Pharmacia Corp Compostos de indazol substituìdos para o tratamento de inflamação
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
BR0314485A (pt) 2002-09-25 2005-07-26 Memory Pharm Corp Indazóis, benzotiazóis e benzoisotiazóis, composto, composição farmacêutica, método desativação/estimulação seletiva de receptores nicotìnicos de a-7 em um mamìfero e método de tratamento e/ou prevenção de uma doença com os mesmos
KR20050111318A (ko) 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
UA93348C2 (ru) * 2004-03-25 2011-02-10 Меморі Фармас'Ютікалз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
KR101176670B1 (ko) * 2004-03-25 2012-08-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도
CA2594773A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
KR20080048550A (ko) 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
KR20080102181A (ko) 2006-02-15 2008-11-24 알러간, 인코포레이티드 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
JP5179486B2 (ja) 2006-06-28 2013-04-10 アムジエン・インコーポレーテツド グリシン輸送体−１阻害剤
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008097930A1 (en) 2007-02-05 2008-08-14 Amira Pharmaceuticals, Inc. Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
EP2134683A2 (en) 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
NZ582056A (en) 2007-08-10 2012-08-31 Lundbeck & Co As H Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
FR2921342B1 (fr) * 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009155054A2 (en) 2008-05-29 2009-12-23 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
US20100113405A1 (en) 2008-11-06 2010-05-06 Auspex Pharmaceuticals, Inc. Methylindazole modulators of 5-ht3 receptors
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
JP6299097B2 (ja) 2013-07-22 2018-03-28 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体

Also Published As

Publication number Publication date
US20160185801A1 (en) 2016-06-30
JP6275675B2 (ja) 2018-02-07
EP3312169A1 (en) 2018-04-25
EA201590228A1 (ru) 2015-05-29
KR102148969B1 (ko) 2020-08-27
TN2015000018A1 (en) 2016-06-29
AP2015008240A0 (en) 2015-01-31
DOP2015000009A (es) 2015-03-15
CL2015000121A1 (es) 2015-06-12
LT2875011T (lt) 2018-05-10
PH12015500085B1 (en) 2015-04-13
ES2659758T3 (es) 2018-03-19
MX2015000783A (es) 2015-05-07
KR20150036692A (ko) 2015-04-07
GEP201606526B (en) 2016-08-10
JP2015522619A (ja) 2015-08-06
CN106478662B (zh) 2019-07-02
TWI602821B (zh) 2017-10-21
US9670229B2 (en) 2017-06-06
US20160251373A1 (en) 2016-09-01
CN104768943B (zh) 2016-11-16
DK3312169T3 (da) 2021-12-13
US20170260201A1 (en) 2017-09-14
JOP20130213B1 (ar) 2021-08-17
HK1252279A1 (en) 2019-05-24
BR112015001028A2 (pt) 2017-06-27
SI2875011T1 (en) 2018-06-29
JP2016040278A (ja) 2016-03-24
HK1210772A1 (en) 2016-05-06
JP6479145B2 (ja) 2019-03-06
BR112015001028B1 (pt) 2022-12-06
MY182432A (en) 2021-01-25
US9695195B2 (en) 2017-07-04
ME03005B (me) 2018-10-20
UY34912A (es) 2014-02-28
AU2013290375B2 (en) 2017-11-30
ES2897881T3 (es) 2022-03-03
JP5778877B1 (ja) 2015-09-16
CA2879115C (en) 2021-03-02
EP2875011A1 (en) 2015-05-27
CN106478662A (zh) 2017-03-08
US20180072758A1 (en) 2018-03-15
PH12015500085A1 (en) 2015-04-13
PT2875011T (pt) 2018-03-21
ECSP15004780A (es) 2018-07-31
SG11201500302UA (en) 2015-04-29
US9303045B2 (en) 2016-04-05
PL2875011T3 (pl) 2018-07-31
JP2015522618A (ja) 2015-08-06
EP2875012B1 (en) 2019-09-04
JP2015166357A (ja) 2015-09-24
HUE056710T2 (hu) 2022-03-28
US10407443B2 (en) 2019-09-10
PE20150671A1 (es) 2015-05-06
CR20150057A (es) 2015-03-26
US20140024644A1 (en) 2014-01-23
WO2014014951A1 (en) 2014-01-23
EP2875011B1 (en) 2018-01-10
US10125145B2 (en) 2018-11-13
AU2013290375A1 (en) 2015-02-19
RS57096B1 (sr) 2018-06-29
JP2018065827A (ja) 2018-04-26
JP6262729B2 (ja) 2018-01-17
WO2014014962A1 (en) 2014-01-23
CO7280468A2 (es) 2015-05-29
US20150182533A1 (en) 2015-07-02
EA025986B1 (ru) 2017-02-28
EP3312169B1 (en) 2021-09-15
DK2875011T3 (en) 2018-04-16
EP2875012A1 (en) 2015-05-27
US20180327421A1 (en) 2018-11-15
US20150291624A1 (en) 2015-10-15
CN104768943A (zh) 2015-07-08
CA2879115A1 (en) 2014-01-23
AR091781A1 (es) 2015-02-25
IN2015DN00957A (en:Method) 2015-06-12
MX359733B (es) 2018-10-09
PL3312169T3 (pl) 2022-01-24
TW201422626A (zh) 2014-06-16
SMT201800177T1 (it) 2018-05-02
JP5816400B2 (ja) 2015-11-18
ZA201500781B (en) 2016-04-28
IL236702A0 (en) 2015-02-26
US9346829B2 (en) 2016-05-24
NZ704814A (en) 2017-08-25
PT3312169T (pt) 2021-11-12
IL236702B (en) 2018-12-31
HUE038757T2 (hu) 2018-11-28
US9012447B2 (en) 2015-04-21
CY1120881T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
IL233592A0 (en) p2x4 receptor antagonist
ZA201500781B (en) 5-ht3 receptor antagonists
GB201213700D0 (en) Receptor antagnists II
PT2927224T (pt) Antagonistas de receptores
IL238974B (en) cxcr7 antagonists
HUE039607T2 (hu) Progeszteron antagonisták
IL232503A (en) H2 - Indazoles as antagonists of the ep2 receptor
ZA201305576B (en) Trpm8 receptor antagonists
IL235558A0 (en) v1a receptor agonists
IL237477B (en) Chemokine receptor antagonists
GB201223053D0 (en) Receptor
GB201213698D0 (en) Receptor antagonists II
GB201213699D0 (en) Receptor antagonists II
IL230334A0 (en) Non-competitive nicotinic receptor antagonists
GB201304666D0 (en) Dopamine receptor antagonist